Scarica l'app Stockscreener
6.1835
12.77%
0.7035
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Growth or Bubble? Examining BioXcel’s Surge - StocksToTrade
BioXcel Shares Jump After Encouraging FDA Feedback on BXCL501 Home-Use Expansion - MSN
BioXcel Therapeutics stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com
BioXcel Therapeutics Receives Positive FDA Feedback - TipRanks
Bioxcel Therapeutics Soars 34.67% on FDA sNDA Alignment - AInvest
BioXcel receives FDA alignment for IGALMI at-home use submission - Investing.com
BioXcel stock surges after positive FDA feedback on BXCL501 expansion - Investing.com
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers - RTTNews
BioXcel Therapeutics Announces Positive FDA Pre-sNDA - GlobeNewswire
First-Ever At-Home Agitation Drug: BioXcel's IGALMI Moves Closer to Outpatient Bipolar/Schizophrenia Use - Stock Titan
Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement - AInvest
BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label - Stocktwits
Will Breakout in BioXcel Therapeutics Inc. Sustain Through Next WeekJuly 2025 Price Swings & Technical Buy Zone Confirmations - beatles.ru
BioXcel Therapeutics Inc. Testing Reversal Zone on Weekly ChartEarnings Trend Report & Comprehensive Market Scan Insights - sundaytimes.kr
BioXcel Therapeutics Receives Positive FDA Feedback Ahead of Pre-sNDA Meeting - AInvest
BioXcel Therapeutics Price Target Raised to $10 by H.C. Wainwright Analyst - AInvest
Healthcare Stocks Move in After-Market Session: DIH Holding, Tonix Pharmaceuticals, BioXcel Therapeutics Lead Gainers, Tivic Health Systems, CASI Pharmaceuticals Decline as Losers - AInvest
FDA decision coming for BTAI’s at-home agitation drug—will this be the catalyst for a 100% rally - AInvest
Is BioXcel Therapeutics Inc. part of any major indexTrade Volume Summary & AI Enhanced Market Trend Forecasts - thegnnews.com
Bioxcel Therapeutics (BTAI.O) Sees Sharp Intraday Move: What’s Behind the Surge? - AInvest
Bioxcel Therapeutics shares rise 5.68% intraday after HC Wainwright adjusted price target. - AInvest
HC Wainwright Raises PT to $10 for Bioxcel Therapeutics to Buy - AInvest
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $10 From $8, Maintains Buy Rating - MarketScreener
BioXcel Therapeutics price target raised to $10 from $8 at H.C. Wainwright - TipRanks
BioXcel Therapeutics receives FDA feedback ahead of planned pre-sNDA meeting - Investing.com
Any news on BTAI - AInvest
BioXcel Therapeutics at HCW@Home: Expanding Agitation Treatments By Investing.com - Investing.com Canada
BioXcel Therapeutics at HCW@Home: Expanding Agitation Treatments - Investing.com
Published on: 2025-08-15 03:08:57 - thegnnews.com
BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
3 Supercharged Stocks Flashing Strong Momentum Signals - Benzinga
Mizuho Cuts Price Target for BioXcel Amid Neutral Stance - StocksToTrade
Mizuho Slashes BioXcel Therapeutics’ Price Target, Citing Neutral Outlook - timothysykes.com
BioXcel Therapeutics CEO to participate in virtual fireside chat on Aug 14, 2025. - AInvest
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - GlobeNewswire
BioXcel Therapeutics CEO Discusses AI-Driven Neuroscience Pipeline at Virtual Investor Event - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Bioxcel Therapeutics 2025 Q2 Earnings Widened Net Loss Amid Revenue Drop - AInvest
BioXcel Therapeutics Reports Q2 2025 Financial Results - TipRanks
BioXcel Therapeutics to Present at Canaccord Genuity 45th Annual Growth Conference on August 12 - AInvest
Bioxcel Therapeutics Sees Significant Market Potential for BXCL501 in Treating Agitation Episodes - AInvest
BioXcel Therapeutics Surges 6.25% on $230M Volume Ranking 441st as Clinical Pipeline and Patent Expansions Bolster Investor Confidence - AInvest
BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative
BioXcel Therapeutics (BTAI): Assessing the Impact of SERENITY Trial Outcomes on At-Home Agitation Market Potential - AInvest
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials - Investing.com
BioXcel Therapeutics (BTAI) Q2 Financial Report: Wider Loss, Revenue Decrease, and Upcoming Business Updates - AInvest
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
Bioxcel Therapeutics (BTAI) up more than 500% since Jul 31 - AInvest
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Q2 Earnings Miss Estimates, Revenue Down 89.1% Y/Y - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Q2 2025 Financials, Topline Data Expected in August. - AInvest
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel Therapeutics Reports Q2 Earnings, SERENITY At-Home Trial Topline Expected in August. - AInvest
BioXcel Therapeutics Reports Upcoming Topline Data from SERENITY At-Home Phase 3 Trial and Strengthens Financial Position - Quiver Quantitative
BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month - Stock Titan
0.14%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):